A Web Portal for Communicating Polygenic Risk Score Results for Health Care Use—The P5 Study

We present a method for communicating personalized genetic risk information to citizens and their physicians using a secure web portal. We apply the method for 3,177 Finnish individuals in the P5 Study where estimates of genetic and absolute risk, based on genetic and clinical risk factors, of future disease are reported to study participants, allowing individuals to participate in managing their own health. Our method facilitates using polygenic risk score as a personalized tool to estimate a person’s future disease risk while offering a way for health care professionals to utilize the polygenic risk scores as a preventive tool in patient care.

[1]  V. Salomaa,et al.  Communicating polygenic and non-genetic risk for atherosclerotic cardiovascular disease - An observational follow-up study , 2020, medRxiv.

[2]  Cathryn M. Lewis,et al.  Impute.me: An Open-Source, Non-profit Tool for Using Data From Direct-to-Consumer Genetic Testing to Calculate and Interpret Polygenic Risk Scores , 2020, Frontiers in Genetics.

[3]  J. Jonsson,et al.  Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland , 2020, European Journal of Human Genetics.

[4]  E. V. Van Allen,et al.  Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report. , 2020, JCO precision oncology.

[5]  Audrey Y. Chu,et al.  Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers , 2020, Nature Medicine.

[6]  C. Wright,et al.  Direct-to-consumer genetic testing , 2019, BMJ.

[7]  C. Stern,et al.  Treatment of Blood Cholesterol to Reduce Atheroscelerotic Cardiovascular Risk in Adults , 2019, Journal of Contemporary Pharmacy Practice.

[8]  M. Daly,et al.  Polygenic and clinical risk scores and their impact on age at onset of cardiometabolic diseases and common cancers , 2019, bioRxiv.

[9]  M. Feldman,et al.  Analysis of polygenic risk score usage and performance in diverse human populations , 2019, Nature Communications.

[10]  Jeffrey Braithwaite,et al.  Integrating Genomics into Healthcare: A Global Responsibility. , 2019, American journal of human genetics.

[11]  J. Danesh,et al.  Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults , 2018, Journal of the American College of Cardiology.

[12]  Timothy Shin Heng Mak,et al.  Tutorial: a guide to performing polygenic risk score analyses , 2018, bioRxiv.

[13]  H. Pattison,et al.  Type 2 diabetes in adolescents and young adults. , 2018, The lancet. Diabetes & endocrinology.

[14]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[15]  Marc S. Williams,et al.  Implementation of a patient-facing genomic test report in the electronic health record using a web-application interface , 2018, BMC Medical Informatics and Decision Making.

[16]  Roberto Elosua,et al.  The association between education and cardiovascular disease incidence is mediated by hypertension, diabetes, and body mass index , 2017, Scientific Reports.

[17]  Jaak Vilo,et al.  Comparing distributions of polygenic risk scores of type 2 diabetes and coronary heart disease within different populations , 2017, PloS one.

[18]  Dermot F. Reilly,et al.  Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting , 2017, Circulation.

[19]  W. Willett,et al.  Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. , 2016, JAMA oncology.

[20]  M. Bamshad,et al.  My46: a web-based tool for self-guided management of genomic test results in research and clinical settings , 2016, Genetics in Medicine.

[21]  T. Marteau,et al.  The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis , 2016, British Medical Journal.

[22]  Andres Metspalu,et al.  Personalized risk prediction for type 2 diabetes: the potential of genetic risk scores , 2016, Genetics in Medicine.

[23]  Matthew S. Lebo,et al.  A systematic approach to the reporting of medically relevant findings from whole genome sequencing , 2014, BMC Medical Genetics.

[24]  Jennifer G. Robinson,et al.  Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline , 2014, Annals of Internal Medicine.

[25]  H. Willard,et al.  Impact of Delivery Models on Understanding Genomic Risk for Type 2 Diabetes , 2014, Public Health Genomics.

[26]  S. Aunola,et al.  Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS) , 2013, Diabetologia.

[27]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[28]  J. Lindström,et al.  Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study , 2006, The Lancet.

[29]  Jaakko Tuomilehto,et al.  The diabetes risk score: a practical tool to predict type 2 diabetes risk. , 2003, Diabetes care.

[30]  K. Borodulin,et al.  FinHealth 2017 Study : Methods , 2019 .